Reassessment of the risk of narcolepsy in children in England 8 years after receipt of the AS03-adjuvanted H1N1 pandemic vaccine: A case-coverage study

English version

Autoři: Julia Stowe ^aff001; Nick Andrews ^aff002; Paul Gringras ^aff003; Timothy Quinnell ^aff004; Zenobia Zaiwalla ^aff005; John Shneerson ^aff006; Elizabeth Miller ^aff007
Působiště autorů: Immunisation and Countermeasures, Public Health England, London, England ^aff001; Statistics and Modelling Economics Department, Public Health England, London, England ^aff002; Evelina Children’s Hospital, Lambeth, London, England ^aff003; Respiratory Support and Sleep Centre, Royal Papworth Hospital, Cambridge, England ^aff004; John Radcliffe Hospital, Headington, England ^aff005; Royal Papworth Hospital, Cambridge, England ^aff006; Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, England ^aff007
Vyšlo v časopise: Reassessment of the risk of narcolepsy in children in England 8 years after receipt of the AS03-adjuvanted H1N1 pandemic vaccine: A case-coverage study. PLoS Med 17(9): e32767. doi:10.1371/journal.pmed.1003225
Kategorie: Research Article
doi: https://doi.org/10.1371/journal.pmed.1003225

Souhrn

Background

Early studies of narcolepsy after AS03-adjuvanted pandemic A/H1N12009 vaccine (Pandemrix) could not define the duration of elevated risk post-vaccination nor the risk in children aged under 5 years who may not present until much older.

Methods/Findings

Clinical information and sleep test results, extracted from hospital notes at 3 large pediatric sleep centers in England between September 2017 and June 2018 for narcolepsy cases aged 4–19 years with symptom onset since January 2009, were reviewed by an expert panel to confirm the diagnosis. Vaccination histories were independently obtained from general practitioners (GPs). The odds of vaccination in narcolepsy cases compared with the age-matched English population was calculated after adjustment for clinical conditions that were indications for vaccination.

GP questionnaires were returned for 242 of the 244 children with confirmed narcolepsy. Of these 5 were under 5 years, 118 were 5–11 years, and 119 were 12–19 years old at diagnosis; 39 were vaccinated with Pandemrix before onset. The odds ratio (OR) for onset at any time after vaccination was 1.94 (95% confidence interval [CI] 1.30–2.89), The elevated risk period was restricted to onsets within 12 months of vaccination (OR 6.65 [3.44–12.85]) and was highest within the first 6 months. After one year, ORs were not significantly different from 1 up to 8 years after vaccination. The ORs were similar in under five-year-olds and older ages. The estimated attributable risk was 1 in 34,500 doses. Our study is limited by including cases from only 3 sleep centers, who may differ from cases diagnosed in nonparticipating centers, and by imprecision in defining the centers’ catchment population. The potential for biased recall of onset shortly after vaccination in cases aware of the association cannot be excluded.

Conclusions

In this study, we found that vaccine-attributable cases have onset of narcolepsy within 12 months of Pandemrix vaccination. The attributable risk is higher than previously estimated in England because of identification of vaccine-attributable cases with late diagnoses. Absence of a compensatory drop in risk 1–8 years after vaccination suggests that Pandemrix does not trigger onsets in those in whom narcolepsy would have occurred later.

Klíčová slova:

England – H1N1 – Influenza – Medical risk factors – Narcolepsy – Pandemics – Vaccination and immunization – Vaccines

Zdroje

1. Partinen M, Saarenpaa-Heikkila O, Ilveskoski I, Hublin C, Linna M, Olsen P, et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS ONE. 2012;7(3):e33723. doi: 10.1371/journal.pone.0033723 22470463; PubMed Central PMCID: PMC3314680.

2. Persson I, Granath F, Askling J, Ludvigsson JF, Olsson T, Feltelius N. Risks of neurological and immune-related diseases, including narcolepsy, after vaccination with Pandemrix: a population- and registry-based cohort study with over 2 years of follow-up. J Intern Med. 2014;275(2):172–90. doi: 10.1111/joim.12150 24134219.

3. Nohynek H, Jokinen J, Partinen M, Vaarala O, Kirjavainen T, Sundman J, et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PloS ONE. 2012;7(3):e33536. doi: 10.1371/journal.pone.0033536 22470453; PubMed Central PMCID: PMC3314666.

4. Department of Health I, Health Protection Agency. Pandemic H1N1 (Swine) Influenza Vaccine Uptake amongst Patient Groups in Primary Care in England 2009/10 [Internet]. [cited 2020 Aug 25]. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/215977/dh_121014.pdf

5. Miller E, Andrews N, Stellitano L, Stowe J, Winstone AM, Shneerson J, et al. Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. BMJ. 2013;346:f794. doi: 10.1136/bmj.f794 23444425.

6. Stowe J, Andrews N, Kosky C, Dennis G, Eriksson S, Hall A, et al. Risk of Narcolepsy after AS03 Adjuvanted Pandemic A/H1N1 2009 Influenza Vaccine in Adults: A Case-Coverage Study in England. Sleep. 2016;39(5):1051–7. doi: 10.5665/sleep.5752 26856903; PubMed Central PMCID: PMC4835303.

7. Sarkanen TO, Alakuijala APE, Dauvilliers YA, Partinen MM. Incidence of narcolepsy after H1N1 influenza and vaccinations: Systematic review and meta-analysis. Sleep Med Rev. 2018;38:177–86. doi: 10.1016/j.smrv.2017.06.006 28847694.

8. Sturkenboom MC. The narcolepsy-pandemic influenza story: can the truth ever be unraveled? Vaccine. 2015;33 Suppl 2:B6–B13. Epub 2015/05/30. doi: 10.1016/j.vaccine.2015.03.026 26022571.

9. Verstraeten T, Cohet C, Dos Santos G, Ferreira GL, Bollaerts K, Bauchau V, et al. Pandemrix and narcolepsy: A critical appraisal of the observational studies. Hum Vaccin Immunother. 2016;12(1):187–93. Epub 2015/09/18. doi: 10.1080/21645515.2015.1068486 PubMed Central PMCID: PMC4962758. 26379011

10. Health and Social Care Information Centre. Hospital Episode Statistics 2016 [27/07/2016]. [cited 2020 Aug 25]. Available from: http://www.hscic.gov.uk/hes

11. American Academy of Sleep Medicine. International classification of sleep disorders. 3rd ed. Darien, IL: American Academy of Sleep Medicine; 2014.

12. Farrington CP. Control without separate controls: evaluation of vaccine safety using case-only methods. Vaccine. 2004;22(15–16):2064–70. doi: 10.1016/j.vaccine.2004.01.017 15121324.

13. The Clinical Practice Research Datalink (CPRD) [Internet]. [cited 2020 Aug 25]. Available from: http://www.cprd.com

14. Office for National Statistics, Population Estimates Unit. Estimated resident population mid year [Internet]. [cited 2020 Aug 25]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates

15. Stowe J, Andrews N, Miller E. Do Vaccines Trigger Neurological Diseases? Epidemiological Evaluation of Vaccination and Neurological Diseases Using Examples of Multiple Sclerosis, Guillain-Barre Syndrome and Narcolepsy. CNS Drugs. 2019. Epub 2019/10/03. doi: 10.1007/s40263-019-00670-y 31576507.

16. Granath F, Gedeborg R, Smedje H, Feltelius N. Change in risk for narcolepsy over time and impact of definition of onset date following vaccination with AS03 adjuvanted pandemic A/H1N1 influenza vaccine (Pandemrix) during the 2009 H1N1 influenza pandemic. Pharmacoepidemiol Drug Saf. 2019;28(8):1045–53. Epub 2019/05/08. doi: 10.1002/pds.4788 31062443.

17. Oberle D, Pavel J, Mayer G, Geisler P, Keller-Stanislawski B, German Narcolepsy Study G. Retrospective multicenter matched case-control study on the risk factors for narcolepsy with special focus on vaccinations (including pandemic influenza vaccination) and infections in Germany. Sleep medicine. 2017;34:71–83. Epub 2017/05/20. doi: 10.1016/j.sleep.2017.02.026 28522102.

18. Weibel D, Sturkenboom M, Black S, de Ridder M, Dodd C, Bonhoeffer J, et al. Narcolepsy and adjuvanted pandemic influenza A (H1N1) 2009 vaccines–Multi-country assessment. Vaccine. 2018. doi: 10.1016/j.vaccine.2018.08.008 30122647.

19. Montplaisir J, Petit D, Quinn MJ, Ouakki M, Deceuninck G, Desautels A, et al. Risk of narcolepsy associated with inactivated adjuvanted (AS03) A/H1N1 (2009) pandemic influenza vaccine in Quebec. PloS ONE. 2014;9(9):e108489. doi: 10.1371/journal.pone.0108489 25264897; PubMed Central PMCID: PMC4180737.

20. Sarkanen T, Alakuijala A, Julkunen I, Partinen M. Narcolepsy Associated with Pandemrix Vaccine. Curr Neurol Neurosci Rep. 2018;18(7):43. Epub 2018/06/02. doi: 10.1007/s11910-018-0851-5 29855798.

21. Edwards K, Hanquet G, Black S, Mignot E, Jankosky C, Shimabukuro T, et al. Meeting report narcolepsy and pandemic influenza vaccination: What we know and what we need to know before the next pandemic? A report from the 2nd IABS meeting. Biologicals. 2019;60:1–7. Epub 2019/05/28. doi: 10.1016/j.biologicals.2019.05.005 31130313; PubMed Central PMCID: PMC6668612.

22. Han F, Lin L, Warby SC, Faraco J, Li J, Dong SX, et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Annals of neurology. 2011;70(3):410–7. Epub 2011/08/26. doi: 10.1002/ana.22587 21866560.

23. Huang WT, Huang YS, Hsu CY, Chen HC, Lee HC, Lin HC, et al. Narcolepsy and 2009 H1N1 pandemic vaccination in Taiwan. Sleep Medicine. 2018. Epub 2018/12/24. doi: 10.1016/j.sleep.2018.10.036 30579702.

24. Edwards K, Lambert PH, Black S. Narcolepsy and Pandemic Influenza Vaccination: What We Need to Know to be Ready for the Next Pandemic. Pediatr Infect Dis J. 2019;38(8):873–6. Epub 2019/07/16. doi: 10.1097/INF.0000000000002398 31306400.

25. Lansbury LE, Smith S, Beyer W, Karamehic E, Pasic-Juhas E, Sikira H, et al. Effectiveness of 2009 pandemic influenza A(H1N1) vaccines: A systematic review and meta-analysis. Vaccine. 2017;35(16):1996–2006. Epub 2017/03/18. doi: 10.1016/j.vaccine.2017.02.059 28302409.

26. US Food & Drug Administration. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, manufactured by ID Biomedical Corporation–Questions and Answers [06/11/2019]. [cited 2020 Aug 25]. Available from: https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/influenza-h5n1-virus-monovalent-vaccine-adjuvanted-manufactured-id-biomedical-corporation-questions

Článek Providing TB and HIV outreach services to internally displaced populations in Northeast Nigeria: Results of a controlled intervention study

Článek Patterns of beverage purchases amongst British households: A latent class analysis

Článek COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology

Článek The proportion of endometrial tumours associated with Lynch syndrome (PETALS): A prospective cross-sectional study

Článek Mediterranean diet and endothelial function in patients with coronary heart disease: An analysis of the CORDIOPREV randomized controlled trial

Článek Social capital, social cohesion, and health of Syrian refugee working children living in informal tented settlements in Lebanon: A cross-sectional study

Článek Biannual azithromycin distribution and child mortality among malnourished children: A subgroup analysis of the MORDOR cluster-randomized trial in Niger

Článek Mental health problems among female sex workers in low- and middle-income countries: A systematic review and meta-analysis

Článek The relationship between circulating lipids and breast cancer risk: A Mendelian randomization study

Článek Severe mental illness diagnosis in English general hospitals 2006-2017: A registry linkage study

Článek Association between metabolic surgery and cardiovascular outcome in patients with hypertension: A nationwide matched cohort study

Článek Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: A Danish nationwide cohort study